Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Tumorad by Spago Nanomedical for Metastatic Breast Cancer: Likelihood of Approval
Tumorad is under clinical development by Spago Nanomedical and currently in Phase II for Metastatic Breast Cancer. According to GlobalData,...
Tumorad by Spago Nanomedical for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval
Tumorad is under clinical development by Spago Nanomedical and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According...
Tumorad by Spago Nanomedical for Breast Cancer: Likelihood of Approval
Tumorad is under clinical development by Spago Nanomedical and currently in Phase II for Breast Cancer. According to GlobalData, Phase...